β-Casomorphin, bovine (TFA)

β-Casomorphin, bovine TFA (β-Casomorphin-7 (bovine) TFA) is a opioid peptide with an IC₅₀ of 14 μM in an Opioid receptors binding assay^[1]. IC50 & Target: IC50: 14 μM (Opioid receptor)^[1] In Vitro: β-Casomorphin, bovine TFA (0.1μM; 30 minutes-24 hours) stimulates the secretion of mucin in DHE Cells after 8 h of treatment^[2].
β-Casomorphin, bovine TFA (0.1μM; 24 hours) induces an increase in rMuc2 and rMuc3 mRNA levels^[2].
β-Casomorphin, bovine TFA does not modify the expression of rMuc1, rMuc4, and rMuc5AC^[2].
β-Casomorphin, bovine TFA (0.1μM; 24 hours) stimulates MUC5AC expression and mucin Secretion in HT29-MTX Cells (human)^[2].
In Vivo: β-Casomorphin, bovine TFA (7.5×10⁻⁶ mol/day/kg ; i.g.; for 30 days) increases plasma insulin and decreased plasma glucagon of diabetic rats^[3].
β-Casomorphin, bovine TFA (7.5×10⁻⁶ mol/day/kg ; i.g.; for 30 days) alters the changes of SOD, GPx, T-AOC, MDA and H2O2 in the kidney of diabetic rats^[3].
β-Casomorphin, bovine TFA (7.5×10⁻⁶ mol/day/kg ; i.g.; for 30 days) reduces MDA (significantly) and H2O2 (non-significantly) level in the kidney compared to the diabetic rats^[3].
β-Casomorphin, bovine TFA (7.5×10⁻⁶ mol/day/kg ; i.g.; for 30 days) alleviates high glucose-induced decreasement in SOD and GPx activity, increasement in MDA contents in the NRK-52E cells^[3].